KRON Kronos Bio

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.

Kronos Bio President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in the “Novel Oncology Targets” panel discussion on Tuesday, March 5, at 9:10 a.m. ET.

A live audio webcast of the event will be available on the Investors and Media section of the Kronos Bio website at . A replay of the webcast will be available for 30 days following the event.

About Kronos Bio, Inc.

Kronos Bio is a biopharmaceutical company that is advancing an investigational CDK9 inhibitor compound, KB-0742, in clinical trials as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors as well as a preclinical development candidate, KB-9558, targeting the KAT domain of p300 for multiple myeloma. The Company’s scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit / or follow the Company on LinkedIn.

Media Contact:

Sarah Connors

Vice President of Corporate Affairs, Kronos Bio

857-290-7305

Investor Contact:

Margaux Bennett

Vice President, Business Development and Investor Relations, Kronos Bio

650-781-5026



EN
27/02/2024

Underlying

KRONKronos Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kronos Bio

 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio Reports First-Quarter 2024 Financial Results

Kronos Bio Reports First-Quarter 2024 Financial Results — $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 — — KB-9558 remains on track with IND-enabling studies expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company ded...

May 9, 2024 1 EN
 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at...

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 (), at the American Society of Clinical Oncology (ASCO) Annual ...

April 24, 2024 1 EN
 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Ful...

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 $175.0 million in cash, cash equivalents and investments as of December 31, 2023, providing expected cash runway into the second half of 2026 SAN MA...

March 21, 2024 1 EN
 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio Announces Restructuring to Focus Resources on Clinical Deve...

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence in 2025 Restructuring plan extends anticipated cash runway into the second half of 2026 Company to continue to focus discovery efforts on maturing projects and Genentech collaboration activities SAN MAT...

March 7, 2024 1 EN
 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California. “We are excited to present our data at AACR showing that targeting p300’s enzymatic KAT domain can selectively downregulate IRF4, a long sou...

March 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch